MarketCap
Facebook
X
TelegramQuarterly report 2025-Q1
added 05-13-2025
iCAD Balance Sheet 2011-2026 | ICAD
Annual Balance Sheet iCAD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-16.8 M | -21.2 M | -20.6 M | -33.1 M | -20.2 M | 4.58 M | 890 K | -3.45 M | -8.5 M | -14.2 M | -21.6 M | 3.77 M | 898 K | -4.58 M |
Long Term Debt |
133 K | 273 K | 455 K | 266 K | 6.96 M | 15.6 M | 11.2 M | 5.12 M | - | - | 5.6 M | 11.8 M | 14.8 M | - |
Long Term Debt Current |
229 K | 188 K | 217 K | 889 K | - | 795 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 17.8 M | 11.6 M | 5.78 M | 758 K | 1.62 M | 8.94 M | 15.1 M | 17.7 M | 3.22 M |
Total Current Liabilities |
7.56 M | 6.75 M | 13.5 M | 15 M | 16.8 M | 18.8 M | 13.2 M | 12.1 M | 12.9 M | 14.3 M | 22 M | 22.5 M | 14.6 M | 12.5 M |
Total Liabilities |
8.86 M | 8 M | 16.8 M | 15.7 M | 25.1 M | 36.7 M | 24.8 M | 17.9 M | 13.6 M | 15.9 M | 31 M | 37.5 M | 32.3 M | 15.7 M |
Deferred Revenue |
3.86 M | 3.4 M | 3.65 M | 5.65 M | 6.12 M | 5.25 M | 5.16 M | 5.4 M | 5.37 M | 7.5 M | 9.12 M | 8.31 M | 6.52 M | 5.76 M |
Retained Earnings |
-277 M | -272 M | -267 M | -253 M | -242 M | -224 M | -211 M | -202 M | -188 M | -178 M | -145 M | -144 M | -136 M | -127 M |
Total Assets |
37.5 M | 41.4 M | 51.7 M | 62.2 M | 55.6 M | 41.7 M | 31.7 M | 32.1 M | 38.7 M | 48.6 M | 93.8 M | 58.9 M | 60 M | 51.8 M |
Cash and Cash Equivalents |
17.2 M | 21.7 M | 21.3 M | 34.3 M | 27.2 M | 15.3 M | 12.2 M | 9.39 M | 8.58 M | 15.3 M | 32.2 M | 11.9 M | 13.9 M | 4.58 M |
Book Value |
28.7 M | 33.4 M | 34.9 M | 46.5 M | 30.5 M | 5.07 M | 6.9 M | 14.3 M | 25 M | 32.7 M | 62.8 M | 21.4 M | 27.7 M | 36.1 M |
Total Shareholders Equity |
28.7 M | 33.4 M | 34.9 M | 46.5 M | 30.5 M | 5.07 M | 6.9 M | 14.3 M | 25 M | 32.7 M | 62.8 M | 21.4 M | 27.7 M | 36.1 M |
All numbers in USD currency
Quarterly Balance Sheet iCAD
| 2025-Q1 | 2024-Q4 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
73 K | 133 K | 249 K | - | 273 K | 2.48 M | 2.64 M | 2.8 M | 2.48 M | 2.6 M | 54 K | 266 K | 431 K | 646 K | 860 K | 1.08 M | 1.29 M | 1.5 M | 1.71 M | 1.84 M | 1.55 M | 3 K | 8 K | 38 K | 38 K | 38 K | 38 K | - | 5.61 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
8.68 M | 8.86 M | 7.98 M | - | 8 M | 14.7 M | 15.8 M | 16.8 M | 17.7 M | 17.4 M | 15.1 M | 15.7 M | 15.9 M | 15.5 M | 22.1 M | 25.1 M | 25.1 M | 25.1 M | 25.1 M | 36.7 M | 36.7 M | 36.7 M | 36.7 M | 24.8 M | 24.8 M | 24.8 M | 24.8 M | 17.9 M | 17.9 M | 17.9 M | 17.9 M | 13.6 M | 13.6 M | 13.6 M | 13.6 M | 15.9 M | 15.9 M | 15.9 M | 15.9 M | 31 M | 31 M | 31 M | 31 M | 37.5 M | 37.5 M | 37.5 M | 37.5 M | 32.3 M | 32.3 M | 32.3 M | 32.3 M | 15.7 M | 15.7 M | 15.7 M | 15.7 M |
Deferred Revenue |
3.95 M | 3.86 M | 3.32 M | - | 3.4 M | 6.03 M | 6.21 M | 6.22 M | 6.13 M | 6.17 M | 5.76 M | 5.65 M | 5.93 M | 5.96 M | 5.96 M | 6.12 M | 6.12 M | 6.12 M | 6.12 M | 5.25 M | 5.25 M | 5.25 M | 5.25 M | 5.16 M | 5.16 M | 5.16 M | 5.16 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.37 M | 5.37 M | 5.37 M | 5.37 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 9.12 M | 9.12 M | 9.12 M | 9.12 M | 8.31 M | 8.31 M | 8.31 M | 8.31 M | 6.52 M | 6.52 M | 6.52 M | 6.52 M | 5.76 M | 5.76 M | 5.76 M | 5.76 M |
Retained Earnings |
-278 M | -277 M | -275 M | - | -272 M | -272 M | -271 M | -267 M | -264 M | -260 M | -257 M | -253 M | -249 M | -247 M | -244 M | -242 M | -242 M | -242 M | -242 M | -224 M | -224 M | -224 M | -224 M | -211 M | -211 M | -211 M | -211 M | -202 M | -202 M | -202 M | -202 M | -188 M | -188 M | -188 M | -188 M | -178 M | -178 M | -178 M | -178 M | -145 M | -145 M | -145 M | -145 M | -144 M | -144 M | -144 M | -144 M | -136 M | -136 M | -136 M | -136 M | -127 M | -127 M | -127 M | -127 M |
Total Assets |
39.5 M | 37.5 M | 38.9 M | - | 41.4 M | 44.8 M | 47.5 M | 51.7 M | 55.4 M | 58.4 M | 58.8 M | 62.2 M | 65.7 M | 66.6 M | 75.5 M | 55.6 M | 55.6 M | 55.6 M | 55.6 M | 41.7 M | 41.7 M | 41.7 M | 41.7 M | 31.7 M | 31.7 M | 31.7 M | 31.7 M | 32.1 M | 32.1 M | 32.1 M | 32.1 M | 38.7 M | 38.7 M | 38.7 M | 38.7 M | 48.6 M | 48.6 M | 48.6 M | 48.6 M | 93.8 M | 93.8 M | 93.8 M | 93.8 M | 58.9 M | 58.9 M | 58.9 M | 58.9 M | 60 M | 60 M | 60 M | 60 M | 51.8 M | 51.8 M | 51.8 M | 51.8 M |
Cash and Cash Equivalents |
20 M | 17.2 M | 20.4 M | - | 21.7 M | 19 M | 19.7 M | 21.3 M | 24.6 M | 27.2 M | 29.8 M | 34.3 M | 35.8 M | 37.9 M | 46.9 M | 27.2 M | 27.2 M | 27.2 M | 27.2 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 9.39 M | 9.39 M | 9.39 M | 9.39 M | 8.58 M | 8.58 M | 8.58 M | 8.58 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 32.2 M | 32.2 M | 32.2 M | 32.2 M | 11.9 M | 11.9 M | 11.9 M | 11.9 M | 13.9 M | 13.9 M | 13.9 M | 13.9 M | 4.58 M | 4.58 M | 4.58 M | 4.58 M |
Book Value |
30.8 M | 28.7 M | 31 M | - | 33.4 M | 30.2 M | 31.7 M | 34.9 M | 37.7 M | 41 M | 43.8 M | 46.5 M | 49.8 M | 51 M | 53.4 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 5.07 M | 5.07 M | 5.07 M | 5.07 M | 6.9 M | 6.9 M | 6.9 M | 6.9 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 25 M | 25 M | 25 M | 25 M | 32.7 M | 32.7 M | 32.7 M | 32.7 M | 62.8 M | 62.8 M | 62.8 M | 62.8 M | 21.4 M | 21.4 M | 21.4 M | 21.4 M | 27.7 M | 27.7 M | 27.7 M | 27.7 M | 36.1 M | 36.1 M | 36.1 M | 36.1 M |
Total Shareholders Equity |
30.8 M | 28.7 M | 31 M | 32.5 M | 33.4 M | 30.2 M | 31.7 M | 34.9 M | 37.7 M | 41 M | 43.8 M | 46.5 M | 49.8 M | 51 M | 53.4 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 5.07 M | 5.07 M | 5.07 M | 5.07 M | 6.9 M | 6.9 M | 6.9 M | 6.9 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 25 M | 25 M | 25 M | 25 M | 32.7 M | 32.7 M | 32.7 M | 32.7 M | 62.8 M | 62.8 M | 62.8 M | 62.8 M | 21.4 M | 21.4 M | 21.4 M | 21.4 M | 27.7 M | 27.7 M | 27.7 M | 27.7 M | 36.1 M | 36.1 M | 36.1 M | 36.1 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of iCAD, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Health information services
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B |  USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
Evolent Health
EVH
|
$ 2.64 | -1.31 % | $ 247 M | USA |
 |
HealthStream
HSTM
|
$ 19.91 | -1.24 % | $ 605 M | USA |
 |
Health Catalyst
HCAT
|
$ 1.84 | -7.54 % | $ 111 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
HealthEquity
HQY
|
$ 73.39 | -4.6 % | $ 6.28 B | USA |
 |
American Well Corporation
AMWL
|
$ 4.47 | 3.47 % | $ 67 M | USA |
 |
So-Young International
SY
|
$ 3.47 | -6.35 % | $ 275 M |  China |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 2.17 | -2.91 % | $ 837 M | USA |
 |
Omnicell
OMCL
|
$ 36.4 | -3.75 % | $ 1.68 B | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 8.0 | -13.33 % | $ 137 M | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
Progyny
PGNY
|
$ 20.97 | -2.71 % | $ 1.8 B | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Phreesia
PHR
|
$ 11.88 | -4.96 % | $ 648 M | USA |
 |
Zhongchao
ZCMD
|
$ 0.22 | -8.99 % | $ 1.15 M | China |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Schrödinger
SDGR
|
$ 11.39 | -4.97 % | $ 828 M | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
10x Genomics
TXG
|
$ 17.63 | -7.94 % | $ 2.07 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
Teladoc Health
TDOC
|
$ 4.44 | -5.13 % | $ 757 M | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Veeva Systems
VEEV
|
$ 172.07 | -2.81 % | $ 27.6 B | USA |
 |
SCWorx Corp.
WORX
|
$ 0.26 | 41.67 % | $ 379 K | USA |